FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

A correction has been published: N Engl J Med 2006;355(16):1746.

Previous Volume 350:1081-1092 March 11, 2004 Number 11 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set Supplementary Material Editorial by Piccart-Gebhart, M. J. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article Related Article PubMed Citation

ABSTRACT

Background Tamoxifen, taken for five years, is the standard adjuvant treatment for postmenopausal women with primary, estrogen-receptor–positive breast cancer. Despite this treatment, however, some patients have a relapse.

Methods We conducted a double-blind, randomized trial to test whether, after two to three years of tamoxifen therapy, switching to exemestane was more effective than continuing tamoxifen therapy for the remainder of the five years of treatment. The primary end point was disease-free survival.

Results Of the 4742 patients enrolled, 2362 were randomly assigned to switch to exemestane, and 2380 to continue to receive tamoxifen. After a median follow-up of 30.6 months, 449 first events (local or metastatic recurrence, contralateral breast cancer, or death) were reported — 183 in the exemestane group and 266 in the tamoxifen group. The unadjusted hazard ratio in the exemestane group as compared with the tamoxifen group was 0.68 (95 percent confidence interval, 0.56 to 0.82; P<0.001 by the log-rank test), representing a 32 percent reduction in risk and corresponding to an absolute benefit in terms of disease-free survival of 4.7 percent (95 percent confidence interval, 2.6 to 6.8) at three years after randomization. Overall survival was not significantly different in the two groups, with 93 deaths occurring in the exemestane group and 106 in the tamoxifen group. Severe toxic effects of exemestane were rare. Contralateral breast cancer occurred in 20 patients in the tamoxifen group and 9 in the exemestane group (P=0.04).

Conclusions Exemestane therapy after two to three years of tamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxifen treatment.

Source Information

From the Department of Cancer Medicine, Imperial College and Charing Cross Hospital, London (R.C.C., L.J.G., C.F.S.); Institute of Cancer Research, Sutton (E.H., J.M.B.); South West Wales Cancer Institute, Swansea (G.B.); Cookridge Hospital, Leeds (D.D.); Cancer Research Centre, Weston Park Hospital, Sheffield (R.E.C.); Psychosocial Oncology Group, University of Sussex, Brighton (L.J.F.); Christie Hospital, Manchester (A.S.); and Ysbyty Gwynedd, Bangor, Gwynedd (N.S.) — all in the United Kingdom; Universitair Ziekenhuis, Leuven, Belgium (R.P.); Medical University of Gdansk, Gdansk, Poland (J.J.); Centre François Baclesse, Caen, France (T.D.); U.S. Oncology Research, Houston (S.E.J.); Hospital Donostia, San Sebastián, Spain (I.A.); University of Regensburg, Regensburg, Germany (O.O.); University of Sydney, Sydney, Australia (A.S.C.); Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy (E.B.); Instituto Angel Roffo, Buenos Aires, Argentina (E.M.); Århus University Hospital, Århus, Denmark (J.A.); Haukeland Hospital, University of Bergen, Bergen, Norway (P.E.L.); University Hospital, Parma, Italy (G.C.); and Pharmacia Italia, Pfizer Group, Nerviano, Italy (M.C., G.M.).

Address reprint requests to Dr. Coombes at the Department of Cancer Medicine, Imperial College London, 6th Fl., Cyclotron Bldg., Hammersmith Hospital, Du Cane Rd., London W12 0NN, United Kingdom.

Full Text of this Article

Related Letters:

Adjuvant Treatment of Breast Cancer with Exemestane
Kunkler I. H., Vakaet L. A.M.L., De Neve W., Tanvetyanon T., Coombes R. C., Bliss J. M., Hall E.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:100-102, Jul 1, 2004. Correspondence

This article has been cited by other articles:

• Song, H., Shahverdi, K., Huso, D. L., Esaias, C., Fox, J., Liedy, A., Zhang, Z., Reilly, R. T., Apostolidis, C., Morgenstern, A., Sgouros, G. (2008). 213Bi ({alpha}-Emitter)-Antibody Targeting of Breast Cancer Metastases in the neu-N Transgenic Mouse Model. Cancer Res. 68: 3873-3880 [Abstract] [Full Text]  
• Hayes, D. F., Stearns, V., Rae, J., Flockhart, D., on behalf of the Consortium on Breast Cancer Pharm, (2008). A Model Citizen? Is Tamoxifen More Effective Than Aromatase Inhibitors if We Pick the Right Patients?. JNCI J Natl Cancer Inst 100: 610-613 [Full Text]  
• Fountzilas, G., Dafni, U., Gogas, H., Linardou, H., Kalofonos, H. P., Briasoulis, E., Pectasides, D., Samantas, E., Bafaloukos, D., Stathopoulos, G. P., Karina, M., Papadimitriou, C., Skarlos, D., Pisanidis, N., Papakostas, P., Markopoulos, C., Tzorakoeleftherakis, E., Dimitrakakis, K., Makrantonakis, P., Xiros, N., Polichronis, A., Varthalitis, I., Karanikiotis, C., Dimopoulos, A. M. (2008). Postoperative dose-dense sequential chemotherapy with epirubicin, paclitaxel and CMF in patients with high-risk breast cancer: safety analysis of the Hellenic Cooperative Oncology Group randomized phase III trial HE 10/00. Ann Oncol 19: 853-860 [Abstract] [Full Text]  
• Muss, H. B., Tu, D., Ingle, J. N., Martino, S., Robert, N. J., Pater, J. L., Whelan, T. J., Palmer, M. J., Piccart, M. J., Shepherd, L. E., Pritchard, K. I., He, Z., Goss, P. E. (2008). Efficacy, Toxicity, and Quality of Life in Older Women With Early-Stage Breast Cancer Treated With Letrozole or Placebo After 5 Years of Tamoxifen: NCIC CTG Intergroup Trial MA.17. JCO 26: 1956-1964 [Abstract] [Full Text]  
• Mamounas, E. P., Jeong, J.-H., Wickerham, D. L., Smith, R. E., Ganz, P. A., Land, S. R., Eisen, A., Fehrenbacher, L., Farrar, W. B., Atkins, J. N., Pajon, E. R., Vogel, V. G., Kroener, J. F., Hutchins, L. F., Robidoux, A., Hoehn, J. L., Ingle, J. N., Geyer, C. E. Jr, Costantino, J. P., Wolmark, N. (2008). Benefit From Exemestane As Extended Adjuvant Therapy After 5 Years of Adjuvant Tamoxifen: Intention-to-Treat Analysis of the National Surgical Adjuvant Breast and Bowel Project B-33 Trial. JCO 26: 1965-1971 [Abstract] [Full Text]  
• Chia, S., Gradishar, W., Mauriac, L., Bines, J., Amant, F., Federico, M., Fein, L., Romieu, G., Buzdar, A., Robertson, J. F.R., Brufsky, A., Possinger, K., Rennie, P., Sapunar, F., Lowe, E., Piccart, M. (2008). Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptor-Positive, Advanced Breast Cancer: Results From EFECT. JCO 26: 1664-1670 [Abstract] [Full Text]  
• Rudas, M., Lehnert, M., Huynh, A., Jakesz, R., Singer, C., Lax, S., Schippinger, W., Dietze, O., Greil, R., Stiglbauer, W., Kwasny, W., Grill, R., Stierer, M., Gnant, M. F.X., Filipits, M., for the Austrian Breast and Colorectal Cancer Stud, (2008). Cyclin D1 Expression in Breast Cancer Patients Receiving Adjuvant Tamoxifen-Based Therapy. Clin. Cancer Res. 14: 1767-1774 [Abstract] [Full Text]  
• Farag, N., Burns, R., Come, S. E. (2008). Update: A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. JAMA 299: 1055-1056 [Full Text]  
• Eastell, R., Adams, J. E., Coleman, R. E., Howell, A., Hannon, R. A., Cuzick, J., Mackey, J. R., Beckmann, M. W., Clack, G. (2008). Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. JCO 26: 1051-1057 [Abstract] [Full Text]  
• Mamounas, E. P. (2008). Facilitating Breast-Conserving Surgery and Preventing Recurrence: Aromatase Inhibitors in the Neoadjuvant and Adjuvant Settings. Ann. Surg. Oncol. 15: 691-703 [Abstract] [Full Text]  
• Trinkaus, M., Chin, S., Wolfman, W., Simmons, C., Clemons, M. (2008). Should Urogenital Atrophy in Breast Cancer Survivors Be Treated with Topical Estrogens?. The Oncologist 13: 222-231 [Abstract] [Full Text]  
• Parton, M., Smith, I. E. (2008). Controversies in the Management of Patients With Breast Cancer: Adjuvant Endocrine Therapy in Premenopausal Women. JCO 26: 745-752 [Full Text]  
• Lin, N. U., Winer, E. P. (2008). Advances in Adjuvant Endocrine Therapy for Postmenopausal Women. JCO 26: 798-805 [Abstract] [Full Text]  
• Greene, R. E., Tsang, V. (2008). Hormonal Therapy for the Treatment of Postmenopausal Breast Cancer Patients. Journal of Pharmacy Practice 21: 36-45 [Abstract]  
• Partridge, A. H., LaFountain, A., Mayer, E., Taylor, B. S., Winer, E., Asnis-Alibozek, A. (2008). Adherence to Initial Adjuvant Anastrozole Therapy Among Women With Early-Stage Breast Cancer. JCO 26: 556-562 [Abstract] [Full Text]  
• Colomer, R., Monzo, M., Tusquets, I., Rifa, J., Baena, J. M., Barnadas, A., Calvo, L., Carabantes, F., Crespo, C., Munoz, M., Llombart, A., Plazaola, A., Artells, R., Gilabert, M., Lloveras, B., Alba, E. (2008). A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma. Clin. Cancer Res. 14: 811-816 [Abstract] [Full Text]  
• Rossi, E., Morabito, A., De Maio, E., Di Rella, F., Esposito, G., Gravina, A., Labonia, V., Landi, G., Nuzzo, F., Pacilio, C., Piccirillo, M. C., D'Aiuto, G., D'Aiuto, M., Rinaldo, M., Botti, G., Gallo, C., Perrone, F., de Matteis, A. (2008). Endocrine Effects of Adjuvant Letrozole + Triptorelin Compared With Tamoxifen + Triptorelin in Premenopausal Patients With Early Breast Cancer. JCO 26: 264-270 [Abstract] [Full Text]  
• Bruzzi, P. (2008). Non-drug industry funded research. BMJ 336: 1-2 [Full Text]  
• Rugo, H. S. (2008). The breast cancer continuum in hormone-receptor positive breast cancer in postmenopausal women: evolving management options focusing on aromatase inhibitors. Ann Oncol 19: 16-27 [Abstract] [Full Text]  
• Bird, B. R.J. H., Swain, S. M. (2008). Cardiac Toxicity in Breast Cancer Survivors: Review of Potential Cardiac Problems. Clin. Cancer Res. 14: 14-24 [Abstract] [Full Text]  
• Jordan, V. C., O'Malley, B. W. (2007). Selective Estrogen-Receptor Modulators and Antihormonal Resistance in Breast Cancer. JCO 25: 5815-5824 [Abstract] [Full Text]  
• Mouridsen, H., Keshaviah, A., Coates, A. S., Rabaglio, M., Castiglione-Gertsch, M., Sun, Z., Thurlimann, B., Mauriac, L., Forbes, J. F., Paridaens, R., Gelber, R. D., Colleoni, M., Smith, I., Price, K. N., Goldhirsch, A. (2007). Cardiovascular Adverse Events During Adjuvant Endocrine Therapy for Early Breast Cancer Using Letrozole or Tamoxifen: Safety Analysis of BIG 1-98 Trial. JCO 25: 5715-5722 [Abstract] [Full Text]  
• Prowell, T. M., Stearns, V. (2007). Extended Adjuvant Therapy for Breast Cancer How Much Is Enough?. JNCI J Natl Cancer Inst 99: 1825-1827 [Full Text]  
• Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., Brauch, H. (2007). Breast Cancer Treatment Outcome With Adjuvant Tamoxifen Relative to Patient CYP2D6 and CYP2C19 Genotypes. JCO 25: 5187-5193 [Abstract] [Full Text]  
• Mah, V., Seligson, D. B., Li, A., Marquez, D. C., Wistuba, I. I., Elshimali, Y., Fishbein, M. C., Chia, D., Pietras, R. J., Goodglick, L. (2007). Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer. Cancer Res. 67: 10484-10490 [Abstract] [Full Text]  
• Ariazi, E. A., Leitao, A., Oprea, T. I., Chen, B., Louis, T., Bertucci, A. M., Sharma, C. G.N., Gill, S. D., Kim, H. R., Shupp, H. A., Pyle, J. R., Madrack, A., Donato, A. L., Cheng, D., Paige, J. R., Jordan, V. C. (2007). Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen. Molecular Cancer Therapeutics 6: 2817-2827 [Abstract] [Full Text]  
• Jones, S. E., Cantrell, J., Vukelja, S., Pippen, J., O'Shaughnessy, J., Blum, J. L., Brooks, R., Hartung, N. L., Negron, A. G., Richards, D. A., Rivera, R., Holmes, F. A., Chittoor, S., Whittaker, T. L., Bordelon, J. H., Ketchel, S. J., Davis, J. C., Ilegbodu, D., Kochis, J., Asmar, L. (2007). Comparison of Menopausal Symptoms During the First Year of Adjuvant Therapy With Either Exemestane or Tamoxifen in Early Breast Cancer: Report of a Tamoxifen Exemestane Adjuvant Multicenter Trial Substudy. JCO 25: 4765-4771 [Abstract] [Full Text]  
• Jones, L. W., Haykowsky, M., Pituskin, E. N., Jendzjowsky, N. G., Tomczak, C. R., Haennel, R. G., Mackey, J. R. (2007). Cardiovascular Reserve and Risk Profile of Postmenopausal Women After Chemoendocrine Therapy for Hormone Receptor Positive Operable Breast Cancer. The Oncologist 12: 1156-1164 [Abstract] [Full Text]  
• Lim, H.-S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.-J., Ro, J. (2007). Clinical Implications of CYP2D6 Genotypes Predictive of Tamoxifen Pharmacokinetics in Metastatic Breast Cancer. JCO 25: 3837-3845 [Abstract] [Full Text]  
• Crew, K. D., Greenlee, H., Capodice, J., Raptis, G., Brafman, L., Fuentes, D., Sierra, A., Hershman, D. L. (2007). Prevalence of Joint Symptoms in Postmenopausal Women Taking Aromatase Inhibitors for Early-Stage Breast Cancer. JCO 25: 3877-3883 [Abstract] [Full Text]  
• Viale, G., Regan, M. M., Maiorano, E., Mastropasqua, M. G., Dell'Orto, P., Rasmussen, B. B., Raffoul, J., Neven, P., Orosz, Z., Braye, S., Ohlschlegel, C., Thurlimann, B., Gelber, R. D., Castiglione-Gertsch, M., Price, K. N., Goldhirsch, A., Gusterson, B. A., Coates, A. S. (2007). Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. JCO 25: 3846-3852 [Abstract] [Full Text]  
• Pietras, R. J., Marquez-Garban, D. C. (2007). Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers. Clin. Cancer Res. 13: 4672-4676 [Full Text]  
• Gralow, J. R. (2007). Bone Density in Breast Cancer: When to Intervene?. JCO 25: 3194-3197 [Full Text]  
• Kaufmann, M., Jonat, W., Hilfrich, J., Eidtmann, H., Gademann, G., Zuna, I., von Minckwitz, G. (2007). Improved Overall Survival in Postmenopausal Women With Early Breast Cancer After Anastrozole Initiated After Treatment With Tamoxifen Compared With Continued Tamoxifen: The ARNO 95 Study. JCO 25: 2664-2670 [Abstract] [Full Text]  
• Lin, N. U., Winer, E. P. (2007). Optimal Use of Aromatase Inhibitors: To Lead or to Follow?. JCO 25: 2639-2641 [Full Text]  
• Hudis, C. A., Barlow, W. E., Costantino, J. P., Gray, R. J., Pritchard, K. I., Chapman, J.-A. W., Sparano, J. A., Hunsberger, S., Enos, R. A., Gelber, R. D., Zujewski, J. A. (2007). Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. JCO 25: 2127-2132 [Abstract] [Full Text]  
• Goss, P. E., Ingle, J. N., Martino, S., Robert, N. J., Muss, H. B., Piccart, M. J., Castiglione, M., Tu, D., Shepherd, L. E., Pritchard, K. I., Livingston, R. B., Davidson, N. E., Norton, L., Perez, E. A., Abrams, J. S., Cameron, D. A., Palmer, M. J., Pater, J. L. (2007). Efficacy of Letrozole Extended Adjuvant Therapy According to Estrogen Receptor and Progesterone Receptor Status of the Primary Tumor: National Cancer Institute of Canada Clinical Trials Group MA.17. JCO 25: 2006-2011 [Abstract] [Full Text]  
• Muss, H. B., Biganzoli, L., Sargent, D. J., Aapro, M. (2007). Adjuvant Therapy in the Elderly: Making the Right Decision. JCO 25: 1870-1875 [Abstract] [Full Text]  
• Crivellari, D., Aapro, M., Leonard, R., von Minckwitz, G., Brain, E., Goldhirsch, A., Veronesi, A., Muss, H. (2007). Breast Cancer in the Elderly. JCO 25: 1882-1890 [Abstract] [Full Text]  
• Schmitz, K. H., Cappola, A. R., Stricker, C. T., Sweeney, C., Norman, S. A. (2007). The Intersection of Cancer and Aging: Establishing the Need for Breast Cancer Rehabilitation. Cancer Epidemiol. Biomarkers Prev. 16: 866-872 [Abstract] [Full Text]  
• Mauriac, L, Keshaviah, A, Debled, M, Mouridsen, H, Forbes, J., Thurlimann, B, Paridaens, R, Monnier, A, Lang, I, Wardley, A, Nogaret, J-M, Gelber, R., Castiglione-Gertsch, M, Price, K., Coates, A., Smith, I, Viale, G, Rabaglio, M, Zabaznyi, N, Goldhirsch, A, On the behalf of BIG 1-98 Collaborative Group and, (2007). Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol 18: 859-867 [Abstract] [Full Text]  
• Loi, S., Haibe-Kains, B., Desmedt, C., Lallemand, F., Tutt, A. M., Gillet, C., Ellis, P., Harris, A., Bergh, J., Foekens, J. A., Klijn, J. G.M., Larsimont, D., Buyse, M., Bontempi, G., Delorenzi, M., Piccart, M. J., Sotiriou, C. (2007). Definition of Clinically Distinct Molecular Subtypes in Estrogen Receptor-Positive Breast Carcinomas Through Genomic Grade. JCO 25: 1239-1246 [Abstract] [Full Text]  
• Morel, B., Marotte, H., Miossec, P. (2007). Will steroidal aromatase inhibitors induce rheumatoid arthritis?. Ann Rheum Dis 66: 557-558 [Full Text]  
• Gnant, M. F.X., Mlineritsch, B., Luschin-Ebengreuth, G., Grampp, S., Kaessmann, H., Schmid, M., Menzel, C., Piswanger-Soelkner, J. C., Galid, A., Mittlboeck, M., Hausmaninger, H., Jakesz, R. (2007). Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group. JCO 25: 820-828 [Abstract] [Full Text]  
• Brufsky, A., Harker, W. G., Beck, J. T., Carroll, R., Tan-Chiu, E., Seidler, C., Hohneker, J., Lacerna, L., Petrone, S., Perez, E. A. (2007). Zoledronic Acid Inhibits Adjuvant Letrozole-Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. JCO 25: 829-836 [Abstract] [Full Text]  
• Kirkegaard, T., McGlynn, L. M., Campbell, F. M., Muller, S., Tovey, S. M., Dunne, B., Nielsen, K. V., Cooke, T. G., Bartlett, J. M.S. (2007). Amplified in Breast Cancer 1 in Human Epidermal Growth Factor Receptor-Positive Tumors of Tamoxifen-Treated Breast Cancer Patients. Clin. Cancer Res. 13: 1405-1411 [Abstract] [Full Text]  
• Cuzick, J., Forbes, J. F., Sestak, I., Cawthorn, S., Hamed, H., Holli, K., Howell, A. (2007). Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. JNCI J Natl Cancer Inst 99: 272-282 [Abstract] [Full Text]  
• Coates, A. S., Keshaviah, A., Thurlimann, B., Mouridsen, H., Mauriac, L., Forbes, J. F., Paridaens, R., Castiglione-Gertsch, M., Gelber, R. D., Colleoni, M., Lang, I., Del Mastro, L., Smith, I., Chirgwin, J., Nogaret, J.-M., Pienkowski, T., Wardley, A., Jakobsen, E. H., Price, K. N., Goldhirsch, A. (2007). Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98. JCO 25: 486-492 [Abstract] [Full Text]  
• Younis, T, Rayson, D, Dewar, R, Skedgel, C (2007). Modeling for cost-effective-adjuvant aromatase inhibitor strategies for postmenopausal women with breast cancer. Ann Oncol 18: 293-298 [Abstract] [Full Text]  
• Chew, H. K., Wun, T., Harvey, D. J., Zhou, H., White, R. H. (2007). Incidence of Venous Thromboembolism and the Impact on Survival in Breast Cancer Patients. JCO 25: 70-76 [Abstract] [Full Text]  
• Greenspan, S. L., Bhattacharya, R. K., Sereika, S. M., Brufsky, A., Vogel, V. G. (2007). Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. J. Clin. Endocrinol. Metab. 92: 131-136 [Abstract] [Full Text]  
• Kennecke, H., Olivotto, I., Speers, C, Norris, B, Chia, S., Bryce, C, Gelmon, K. (2007). Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18: 45-51 [Abstract] [Full Text]  
• Perey, L, Paridaens, R, Hawle, H, Zaman, K, Nole, F, Wildiers, H, Fiche, M, Dietrich, D, Clement, P, Koberle, D, Goldhirsch, A, Thurlimann, B (2007). Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol 18: 64-69 [Abstract] [Full Text]  
• Delea, T., Karnon, J, Goss, P. (2007). Conclusions regarding relative cost-utility of alternative strategies for use of aromatase inhibitors in postmenopausal women with early breast cancer are premature. Ann Oncol 18: 197-198 [Full Text]  
• Chlebowski, R. T., Blackburn, G. L., Thomson, C. A., Nixon, D. W., Shapiro, A., Hoy, M. K., Goodman, M. T., Giuliano, A. E., Karanja, N., McAndrew, P., Hudis, C., Butler, J., Merkel, D., Kristal, A., Caan, B., Michaelson, R., Vinciguerra, V., Del Prete, S., Winkler, M., Hall, R., Simon, M., Winters, B. L., Elashoff, R. M. (2006). Dietary Fat Reduction and Breast Cancer Outcome: Interim Efficacy Results From the Women's Intervention Nutrition Study. JNCI J Natl Cancer Inst 98: 1767-1776 [Abstract] [Full Text]  
• Belosay, A., Brodie, A. M.H., Njar, V. C.O. (2006). Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN/14-1) on Letrozole-Insensitive Breast Cancer Cells. Cancer Res. 66: 11485-11493 [Abstract] [Full Text]  
• Chien, A. J., Goss, P. E. (2006). Aromatase Inhibitors and Bone Health in Women With Breast Cancer. JCO 24: 5305-5312 [Full Text]  
• PONZONE, R., BIGLIA, N., JACOMUZZI, M. E., MARIANI, L., DOMINGUEZ, A., SISMONDI, P. (2006). Antihormones in Prevention and Treatment of Breast Cancer. Ann. N. Y. Acad. Sci. 1089: 143-158 [Abstract] [Full Text]  
• HONG, Y., CHEN, S. (2006). Aromatase Inhibitors: Structural Features and Biochemical Characterization. Ann. N. Y. Acad. Sci. 1089: 237-251 [Abstract] [Full Text]  
• Wang, X., Chen, S. (2006). Aromatase Destabilizer: Novel Action of Exemestane, a Food and Drug Administration-Approved Aromatase Inhibitor. Cancer Res. 66: 10281-10286 [Abstract] [Full Text]  
• Moy, B, Tu, D, Pater, J., Ingle, J., Shepherd, L., Whelan, T., Goss, P. (2006). Clinical outcomes of ethnic minority women in MA.17: a trial of letrozole after 5 years of tamoxifen in postmenopausal women with early stage breast cancer. Ann Oncol 17: 1637-1643 [Abstract] [Full Text]  
• Ponzone, R, Montemurro, F, Maggiorotto, F, Robba, C, Gregori, D, Jacomuzzi, M., Kubatzki, F, Marenco, D, Dominguez, A, Biglia, N, Sismondi, P (2006). Clinical outcome of adjuvant endocrine treatment according to PR and HER-2 status in early breast cancer. Ann Oncol 17: 1631-1636 [Abstract] [Full Text]  
• Perez, E. A. (2006). Appraising Adjuvant Aromatase Inhibitor Therapy. The Oncologist 11: 1058-1069 [Abstract] [Full Text]  
• Guise, T. A. (2006). Bone Loss and Fracture Risk Associated with Cancer Therapy. The Oncologist 11: 1121-1131 [Abstract] [Full Text]  
• Hirbe, A., Morgan, E. A., Uluckan, O., Weilbaecher, K. (2006). Skeletal complications of breast cancer therapies.. Clin. Cancer Res. 12: 6309s-6314s [Abstract] [Full Text]  
• Kendall, A., Dowsett, M. (2006). Novel concepts for the chemoprevention of breast cancer through aromatase inhibition.. Endocr Relat Cancer 13: 827-837 [Abstract] [Full Text]  
• Chau, I, Cunningham, D (2006). Adjuvant therapy in colon cancer--what, when and how?. Ann Oncol 17: 1347-1359 [Abstract] [Full Text]  
• Buzdar, A. U, Robertson, J. F. (2006). Fulvestrant: Pharmacologic Profile Versus Existing Endocrine Agents for the Treatment of Breast Cancer. The Annals of Pharmacotherapy 40: 1572-1582 [Abstract] [Full Text]  
• Moy, B., Goss, P. E. (2006). Estrogen Receptor Pathway: Resistance to Endocrine Therapy and New Therapeutic Approaches.. Clin. Cancer Res. 12: 4790-4793 [Abstract] [Full Text]  
• Perez, E. A., Josse, R. G., Pritchard, K. I., Ingle, J. N., Martino, S., Findlay, B. P., Shenkier, T. N., Tozer, R. G., Palmer, M. J., Shepherd, L. E., Liu, S., Tu, D., Goss, P. E. (2006). Effect of Letrozole Versus Placebo on Bone Mineral Density in Women With Primary Breast Cancer Completing 5 or More Years of Adjuvant Tamoxifen: A Companion Study to NCIC CTG MA.17. JCO 24: 3629-3635 [Abstract] [Full Text]  
• Lin, X., Yu, Y., Zhao, H., Zhang, Y., Manela, J., Tonetti, D. A. (2006). Overexpression of PKC{alpha} is required to impart estradiol inhibition and tamoxifen-resistance in a T47D human breast cancer tumor model. Carcinogenesis 27: 1538-1546 [Abstract] [Full Text]  
• Kim, R., Kaneko, M., Arihiro, K., Emi, M., Tanabe, K., Murakami, S., Osaki, A., Inai, K. (2006). Extranuclear expression of hormone receptors in primary breast cancer. Ann Oncol 17: 1213-1220 [Abstract] [Full Text]  
• Pietras, R. J. (2006). Biologic Basis of Sequential and Combination Therapies for Hormone-Responsive Breast Cancer. The Oncologist 11: 704-717 [Abstract] [Full Text]  
• Ryan, P. D., Goss, P. E. (2006). Adjuvant Hormonal Therapy in Peri- and Postmenopausal Breast Cancer. The Oncologist 11: 718-731 [Abstract] [Full Text]  
• Bunn, P. A. Jr., Dziadziuszko, R., Varella-Garcia, M., Franklin, W. A., Witta, S. E., Kelly, K., Hirsch, F. R. (2006). Biological Markers for Non-Small Cell Lung Cancer Patient Selection for Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy.. Clin. Cancer Res. 12: 3652-3656 [Full Text]  
• Kelloff, G. J., Lippman, S. M., Dannenberg, A. J., Sigman, C. C., Pearce, H. L., Reid, B. J., Szabo, E., Jordan, V. C., Spitz, M. R., Mills, G. B., Papadimitrakopoulou, V. A., Lotan, R., Aggarwal, B. B., Bresalier, R. S., Kim, J., Arun, B., Lu, K. H., Thomas, M. E., Rhodes, H. E., Brewer, M. A., Follen, M., Shin, D. M., Parnes, H. L., Siegfried, J. M., Evans, A. A., Blot, W. J., Chow, W.-H., Blount, P. L., Maley, C. C., Wang, K. K., Lam, S., Lee, J. J., Dubinett, S. M., Engstrom, P. F., Meyskens, F. L. Jr., O'Shaughnessy, J., Hawk, E. T., Levin, B., Nelson, W. G., Hong, W. K., for the AACR Task Force on Cancer Prevention, (2006). Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward. Clin. Cancer Res. 12: 3661-3697 [Abstract] [Full Text]  
• Labrie, F (2006). Future perspectives of selective estrogen receptor modulators used alone and in combination with DHEA.. Endocr Relat Cancer 13: 335-355 [Abstract] [Full Text]  
• McCloskey, E. V. (2006). Aromatase Inhibitors and Bone Health. IBMS BoneKEy 3: 5-13 [Abstract] [Full Text]  
• Smith, I. E., Dowsett, M., Yap, Y.-S., Walsh, G., Lonning, P. E., Santen, R. J., Hayes, D. (2006). Adjuvant Aromatase Inhibitors for Early Breast Cancer After Chemotherapy-Induced Amenorrhoea: Caution and Suggested Guidelines. JCO 24: 2444-2447 [Abstract] [Full Text]  
• Kijima, I., Phung, S., Hur, G., Kwok, S.-L., Chen, S. (2006). Grape Seed Extract Is an Aromatase Inhibitor and a Suppressor of Aromatase Expression. Cancer Res. 66: 5960-5967 [Abstract] [Full Text]  
• Altundag, K., Ibrahim, N. K. (2006). Aromatase inhibitors in breast cancer: an overview.. The Oncologist 11: 553-562 [Abstract] [Full Text]  
• Berry, D. A., Cirrincione, C., Henderson, I. C., Citron, M. L., Budman, D. R., Goldstein, L. J., Martino, S., Perez, E. A., Muss, H. B., Norton, L., Hudis, C., Winer, E. P. (2006). Estrogen-Receptor Status and Outcomes of Modern Chemotherapy for Patients With Node-Positive Breast Cancer. JAMA 295: 1658-1667 [Abstract] [Full Text]  
• Buzdar, A. U., Baum, M., Cuzick, J., Erban, J. K., Chlebowski, R. T., Coates, A. S., Mouridsen, H., Mauriac, L., the BIG 1-98 Collaborative Group, (2006). Letrozole or tamoxifen in early breast cancer.. NEJM 354: 1528-1530 [Full Text]  
• Come, S. E. (2006). A 62-Year-Old Woman With a New Diagnosis of Breast Cancer. JAMA 295: 1434-1442 [Full Text]  
• Giordano, S. H., Duan, Z., Kuo, Y.-F., Hortobagyi, G. N., Freeman, J., Goodwin, J. S. (2006). Impact of a scientific presentation on community treatment patterns for primary breast cancer.. JNCI J Natl Cancer Inst 98: 382-388 [Abstract] [Full Text]  
• Dougherty, S. M, Mazhawidza, W., Bohn, A. R, Robinson, K. A, Mattingly, K. A, Blankenship, K. A, Huff, M. O, McGregor, W. G, Klinge, C. M (2006). Gender difference in the activity but not expression of estrogen receptors {alpha} and {beta} in human lung adenocarcinoma cells.. Endocr Relat Cancer 13: 113-134 [Abstract] [Full Text]  
• Michaud, L. B., Goodin, S. (2006). Cancer-treatment-induced bone loss, part 1. Am J Health Syst Pharm 63: 419-430 [Abstract] [Full Text]  
• Vessella, R. L., Guise, T. A., Susman, E. S., Suva, L. J., Clines, G. A., Kominsky, S. L., Weber, K. L., Chirgwin, J. M., McCauley, L. K., Kozlow, W. (2006). Meeting Report from Skeletal Complications of Malignancy IV: A symposium jointly sponsored by The Paget Foundation for Paget's Disease of Bone and Related Disorders, the National Cancer Institute, and the University of Virginia School of Medicine * April 28-30, 2005 in Bethesda, Maryland, USA. IBMS BoneKEy 3: 15-42 [Full Text]  
• Stanway, S. J., Purohit, A., Woo, L.W. L., Sufi, S., Vigushin, D., Ward, R., Wilson, R. H., Stanczyk, F. Z., Dobbs, N., Kulinskaya, E., Elliott, M., Potter, B. V.L., Reed, M. J., Coombes, R. C. (2006). Phase I Study of STX 64 (667 Coumate) in Breast Cancer Patients: The First Study of a Steroid Sulfatase Inhibitor. Clin. Cancer Res. 12: 1585-1592 [Abstract] [Full Text]  
• Fallowfield, L. J., Bliss, J. M., Porter, L. S., Price, M. H., Snowdon, C. F., Jones, S. E., Coombes, R. C., Hall, E. (2006). Quality of Life in the Intergroup Exemestane Study: A Randomized Trial of Exemestane Versus Continued Tamoxifen After 2 to 3 Years of Tamoxifen in Postmenopausal Women With Primary Breast Cancer. JCO 24: 910-917 [Abstract] [Full Text]  
• Khatcheressian, J. L., Smith, T. J. (2006). Randomized Trial of Long-Term Follow-Up for Early-Stage Breast Cancer: A Comparison of Family Physician Versus Specialist Care. JCO 24: 835-837 [Full Text]  
• Deb, S., Zhou, J., Amin, S. A., Imir, A. G., Yilmaz, M. B., Lin, Z., Bulun, S. E. (2006). A Novel Role of Sodium Butyrate in the Regulation of Cancer-associated Aromatase Promoters I.3 and II by Disrupting a Transcriptional Complex in Breast Adipose Fibroblasts. J. Biol. Chem. 281: 2585-2597 [Abstract] [Full Text]  
• Lonning, P. E. (2006). Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. Ann Oncol 17: 217-225 [Abstract] [Full Text]  
• Ingle, J. N. (2006). Adjuvant Endocrine Therapy for Postmenopausal Women with Early Breast Cancer. Clin. Cancer Res. 12: 1031s-1036s [Abstract] [Full Text]